Completed PHASE1 INTERVENTIONAL 4-arm NCT01951027

Phase I Study GX-G3 in Healthy Subjects (GX-G3)

A Dose-block Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Safety, Tolerability, and PK/PD of GX-G3 After Single SC Administration in Healthy Male Subjects

Sponsor: Genexine, Inc.

Conditions Healthy

Interventions GX-G3 100 μg/kg or Placebo GX-G3 12.5 μg/kg or Placebo GX-G3 25 μg/kg or Placebo GX-G3 50 μg/kg or Placebo

Updated 6 times since 2017 Last updated: Jan 27, 2015 Started: Sep 30, 2013 Primary completion: Jul 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Genexine, Inc. and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genexine, Inc.

Data source: Genexine, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jung-gu, South Korea